FOLFOX rechallenge matched regorafenib in third-line metastatic CRC

▸ TREATMENT

A retrospective study of 122 patients with left-sided, RAS/BRAF wild-type mCRC found that third-line FOLFOX plus bevacizumab rechallenge showed similar outcomes to regorafenib, with the oxaliplatin-free interval potentially influencing treatment response. (Cancers)